Is Semler Scientific, Inc. overvalued or undervalued?

As of 4 August 2025, the valuation grade for Semler Scientific, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. Based on the current metrics, the company appears to be undervalued, with a P/E ratio of 24, an EV to EBITDA of 27.71, and a Price to Book Value of 2.32. In comparison, its peer Axogen, Inc. has a P/E ratio of -146.35, while Bioventus, Inc. shows a P/E of 72.81, highlighting the relative attractiveness of Semler's valuation.
Despite recent challenges reflected in its stock performance, where it has underperformed the S&P 500 over various periods, including a YTD return of -45.39% compared to the S&P 500's 12.22%, the overall valuation metrics suggest that Semler Scientific, Inc. is positioned favorably within its industry.